Trophos completes patient enrolment in a first study of olesoxime in relapsing remitting Multiple Sclerosis

Topline results for olesoxime as add–on therapy to Interferon beta are expected in early 2014

A fresh approach to developing chronic pain therapeutics

Cellectricon will present a novel phenotypic assay at World Pharma Congress 2013, Tues 4th June, 5pm

Degenerative brain disease

Omics experimental methods are becoming critical in many areas of drug discovery, to allow the development of next generation, innovative therapeutics

Interest grows in peptide therapeutics as production techniques improve

The interest for peptide therapeutics has recently intensified, with a growth rate predicted to be quite significantly higher than for other active pharmaceutical ingredients (APIs) overall.

Enabling pharmacogenomics for future therapeutics

Edvin N Munk reports on the importance of single nucleotide polymorphisms (SNPs) to pharmaceutical industry and the work of The SNP Consortium made up by 13 leading pharmaceutical and information organisations.

Bone Therapeutics’ cell therapy products

Bone Therapeutics, the leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces that it has secured its future manufacturing requirements, allowing it to produce its unique bone cell therapy products on a commercial scale.





To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited